ME/CFS Science @mecfsscience.org · 17/09/20267) A big question is: was this analysis planned in advance or they did go searching for a good result in the data? I couldn't find it in the protocol or trial registration but BioVie says the analysis was pre-specified in what they submitted to the FDA. 2100
ME/CFS Science @mecfsscience.org · 17/09/20268 ) It's interesting that most outcomes favour the Bezisterim group. Although there were reportedly few side-effects, it could be that some broke the blinding so that patients knew that they were on the drug. That's a potential limitation. 180
ME/CFS Science @mecfsscience.org · 17/09/20269) The stock of the company dropped by ca. 20% after the announcement, suggesting that investors were not convinced by the subgroup analysis. This is similar to what happened with the phase 2 trial of Bezisterim for Parkinson's Disease in August. 280